Abstract:

Objective To observe the clinical efficacy of triphenylamidine against Clonorchis sinensis for evidence to screen the optimal drug in the treatment of clonorchiasis. Methods By stratified random sampling, patients infected with Clonorchis sinensis, treated in the outpatient department of Wuming District Disease Prevention and Control Center of Nanning City, were included from August 2020 to August 2022, and divided into observational group (treated with tribendimidine) and control group (treated with praziquantel). Then patients in the observational group were sub-grouped into group A (400 mg, single dose), group B (two doses of daily dose every other week), and group C (three doses for three consecutive days). Patients in the control group (group D) were was treated with praziquantel in dose of 800 mg/time, tid, for 3 days. After one month of medication, all patients underwent reexamination to observe the changes of worm eggs and adverse drug reactions before and after treatment, and treatment effect was evaluated. Results In total, 149 patients received medication with tribendimidine, including 45 patients in group A, 51 in group B, and 53 in group C. Ninety-nine patients were treated with praziquantel. Negative conversion rate in for the egg the observational group was 86.67%, 94.12% and 92.45% respectively, and 97.98% for the control group. There was no significant difference in the conversion rate among groups (χ²=7.146, P>0.05). The egg reduction rate was 79.27%, 88.47% and 82.11% in the three sub-groups, respectively, and 87.91% in the control group for patients with mild infection. For patients with moderate infection, the egg reduction rate was 78.86%, 97.43% and 98.65% in the tribendimidine group, and 99.15% in the praziquantel control group. The total incidence of adverse reaction and the average duration of adverse reaction were 5.37% and 3.9 h, and 13.13% and 50.9 h, respectively in the observational group and control group. The incidence and average duration of adverse reaction were lower in the tribendimidine group than in the praziquantel group, with statistical significance (χ²=4.624, t=6.423, both P<0.05). Conclusion Tribenzamidine can be used for clonorchiasis in clinic, because it shows better efficacy and has has lower incidence and duration of adverse reaction compared to praziquantel.

Key words: Tribenzamidine, Praziquantel, Clonorchiasis, Curative effect